Last mentioned: Feb 25, 2026
Institutional Exit
SEC filings reveal a $170 million position liquidation by a major fund.
120% Rally
Stock price reaches a 12-month peak following sustained clinical momentum.
J&J Partnership Expansion
Johnson & Johnson expands the scope of the oral peptide collaboration.
Phase 2 Success
JNJ-2113 reports positive Phase 2 data in plaque psoriasis, triggering milestone payments.
Protagonist Therapeutics has seen its stock price more than double following clinical breakthroughs in its oral peptide portfolio, yet a major institutional investor has liquidated a $170 million position. This tactical exit highlights the tension between clinical optimism and institutional profit-taking as the company nears critical Phase 3 milestones.
This page surfaces every story mentioning Rusfertide across our startup coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running startup beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Rusfertide was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |